Suppr超能文献

破骨细胞和巨噬细胞耗竭可损害 Acvr1 小鼠纤维性骨发育不良进展性异位骨化模型中的异位骨化。

Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Mouse Model of Fibrodysplasia Ossificans Progressiva.

机构信息

Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

The Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

J Bone Miner Res. 2018 Feb;33(2):269-282. doi: 10.1002/jbmr.3304. Epub 2018 Jan 3.

Abstract

Heterotopic ossification (HO) is a clinical condition that often reduces mobility and diminishes quality of life for affected individuals. The most severe form of progressive HO occurs in those with fibrodysplasia ossificans progressiva (FOP; OMIM #135100), a genetic disorder caused by a recurrent heterozygous gain-of-function mutation (R206H) in the bone morphogenetic protein (BMP) type I receptor ACVR1/ALK2. In individuals with FOP, episodes of HO frequently follow injury. The first sign of active disease is commonly an inflammatory "flare-up" that precedes connective tissue degradation, progenitor cell recruitment, and endochondral HO. We used a conditional-on global knock-in mouse model expressing Acvr1 (referred to as Acvr1 ) to investigate the cellular and molecular inflammatory response in FOP lesions following injury. We found that the Acvr1 R206H mutation caused increased BMP signaling in posttraumatic FOP lesions and early divergence from the normal skeletal muscle repair program with elevated and prolonged immune cell infiltration. The proinflammatory cytokine response of TNFα, IL-1β, and IL-6 was elevated and prolonged in Acvr1 lesions and in Acvr1 mast cells. Importantly, depletion of mast cells and macrophages significantly impaired injury-induced HO in Acvr1 mice, reducing injury-induced HO volume by ∼50% with depletion of each cell population independently, and ∼75% with combined depletion of both cell populations. Together, our data show that the immune system contributes to the initiation and development of HO in FOP. Further, the expression of Acvr1 in immune cells alters cytokine expression and cellular response to injury and unveils novel therapeutic targets for treatment of FOP and nongenetic forms of HO. © 2017 American Society for Bone and Mineral Research.

摘要

异位骨化(HO)是一种临床病症,常导致受影响个体的活动能力降低和生活质量下降。在纤维发育不良性骨化症进展型(FOP;OMIM #135100)患者中,会出现最严重形式的进行性 HO,这是一种由骨形态发生蛋白(BMP)I 型受体 ACVR1/ALK2 中的重复杂合功能获得性突变(R206H)引起的遗传性疾病。在 FOP 患者中,HO 发作常继发于损伤。疾病活动的最初迹象通常是炎症“爆发”,随后是结缔组织降解、祖细胞募集和软骨内 HO。我们使用了一个条件性全局敲入小鼠模型来表达 Acvr1(称为 Acvr1 ),以研究损伤后 FOP 病变中的细胞和分子炎症反应。我们发现,Acvr1 R206H 突变导致创伤后 FOP 病变中的 BMP 信号增加,并与正常的骨骼肌修复程序早期分离,免疫细胞浸润增加且持续时间延长。Acvr1 病变和 Acvr1 肥大细胞中的促炎细胞因子 TNFα、IL-1β 和 IL-6 反应升高且持续时间延长。重要的是,肥大细胞和巨噬细胞耗竭可显著抑制 Acvr1 小鼠的损伤诱导性 HO,独立耗竭每种细胞群可使损伤诱导性 HO 体积减少约 50%,联合耗竭两种细胞群则可减少约 75%。总之,我们的数据表明免疫系统参与了 FOP 中 HO 的起始和发展。此外,免疫细胞中 Acvr1 的表达改变了细胞因子表达和对损伤的细胞反应,并为治疗 FOP 和非遗传性 HO 揭示了新的治疗靶点。2017 年美国骨骼与矿物质研究协会。

相似文献

4
An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
J Bone Miner Res. 2012 Aug;27(8):1746-56. doi: 10.1002/jbmr.1637.
7
Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Methods Mol Biol. 2019;1891:247-255. doi: 10.1007/978-1-4939-8904-1_18.
8
Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis.
J Bone Miner Res. 2019 Oct;34(10):1894-1909. doi: 10.1002/jbmr.3760. Epub 2019 Aug 19.
10
Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.
Sci Transl Med. 2016 Nov 23;8(366):366ra163. doi: 10.1126/scitranslmed.aaf1090.

引用本文的文献

2
All Restricted Spines are not Spondyloarthritis: Fibrodysplasia Ossificans Progressiva (FOP) in Monozygotic Twins presenting to Rheumatology Clinic.
Mediterr J Rheumatol. 2025 Jan 8;36(1):128-135. doi: 10.31138/mjr.210524.mta. eCollection 2025 Mar.
5
Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.
J Zhejiang Univ Sci B. 2025 Apr 23;26(4):317-332. doi: 10.1631/jzus.B2300779.
7
Heterotopic ossification: Current developments and emerging potential therapies.
Chin Med J (Engl). 2025 Feb 20;138(4):389-404. doi: 10.1097/CM9.0000000000003244. Epub 2025 Jan 17.
8
Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets.
Int J Biol Sci. 2025 Jan 1;21(2):544-564. doi: 10.7150/ijbs.102297. eCollection 2025.
9
BMP-9 mediates fibroproliferation in fibrodysplasia ossificans progressiva through TGF-β signaling.
EMBO Mol Med. 2025 Jan;17(1):112-128. doi: 10.1038/s44321-024-00174-3. Epub 2024 Dec 3.
10
Mast cell activation by NGF drives the formation of trauma-induced heterotopic ossification.
JCI Insight. 2024 Nov 26;10(1):e179759. doi: 10.1172/jci.insight.179759.

本文引用的文献

1
Heterotopic ossification: Mechanistic insights and clinical challenges.
Bone. 2018 Apr;109:134-142. doi: 10.1016/j.bone.2017.08.025. Epub 2017 Oct 9.
2
Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).
Bone. 2018 Apr;109:259-266. doi: 10.1016/j.bone.2017.08.023. Epub 2017 Aug 26.
3
The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Bone. 2018 Apr;109:210-217. doi: 10.1016/j.bone.2017.06.011. Epub 2017 Jun 16.
5
Progenitors in Peripheral Nerves Launch Heterotopic Ossification.
Stem Cells Transl Med. 2017 Apr;6(4):1109-1119. doi: 10.1002/sctm.16-0347. Epub 2017 Feb 15.
6
Proinflammatory M1 Macrophages Inhibit RANKL-Induced Osteoclastogenesis.
Infect Immun. 2016 Sep 19;84(10):2802-12. doi: 10.1128/IAI.00461-16. Print 2016 Oct.
7
The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.
J Bone Miner Res. 2016 Mar;31(3):650-6. doi: 10.1002/jbmr.2728. Epub 2015 Nov 14.
9
Cell death, clearance and immunity in the skeletal muscle.
Cell Death Differ. 2016 Jun;23(6):927-37. doi: 10.1038/cdd.2015.171. Epub 2016 Feb 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验